Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.58 |
| ▸ | CDC25A | P30304 | 1/20 | 0.56 |
| ▸ | ICMT | O60725 | 1/20 | 0.55 |
| ▸ | DNM2 | P50570 | 4/20 | 0.47 |
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19638822 | 1.00 | CNR2 (0.58) | CNR2CDC25AICMTDNM2CNR1 | |
| SCHEMBL19638754 | 0.84 | CNR2 (0.60) | CNR2CDC25AICMTCNR1 | |
| SCHEMBL29388385 | 0.84 | CNR2 (0.60) | CNR2CDC25AICMTCNR1 | |
| SCHEMBL17464416 | 0.83 | CNR2 (0.61) | CNR2CDC25AICMTCNR1 | |
| SCHEMBL29387653 | 0.83 | CNR2 (0.61) | CNR2CDC25AICMTCNR1 | |
| SCHEMBL13131369 | 0.80 | CDC25A (0.72) | CNR2CDC25AICMTDNM2CNR1 | |
| SCHEMBL5462804 | 0.79 | CDC25A (0.70) | CNR2CDC25AICMTDNM2CNR1 | |
| SCHEMBL10967590 | 0.79 | CDC25A (0.66) | CNR2CDC25AICMTDNM2CNR1 | |
| SCHEMBL19638834 | 0.79 | CNR1 (0.62) | CNR2CNR1 | |
| SCHEMBL29385699 | 0.79 | CNR1 (0.62) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| US-20260076921-A1 | Transdermal Pharmaceutical Formulations for the Treatment of Multiple Sclerosis | PIKE THERAPEUTICS INC (CA) | 2026-03-19 | — | — | US | disclosed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250312359-A1 | Transdermal Delivery of Tetrahydrocannabinol | Pike Therapeutics Inc. (CA) | 2025-10-09 | — | — | US | disclosed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250248948-A1 | Transdermal and/or Topical, Pharmaceutical Formulations Comprising Cannabidiol and/or Tetrahydrocannabinol for the Treatment of Chronic Pain | PIKE THERAPEUTICS INC (CA) | 2025-08-07 | — | — | US | disclosed |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| US-20250186363-A1 | Pharmaceutical Compositions and Methods for Treating Parkinson's Disease | PIKE THERAPEUTICS INC (CA) | 2025-06-12 | — | — | US | disclosed |
| EP-4558135-A1 | CONTINUOUS DELIVERY SYSTEMS COMPRISING A CANNABINOID AND MEDICINAL USES THEREOF | Pike Therapeutics Inc. (CA) | 2025-05-28 | — | — | EP | disclosed |
| WO-2022219468-A1 | TRANSDERMAL DELIVERY OF CANNABIDIOL | PIKE THERAPEUTICS, INC. 1219014 B.C. LTD. (CA) | 2022-10-20 | — | — | WO | disclosed |
| WO-2022217147-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | ROSENFELD MARK J (US) | 2022-10-13 | — | — | WO | disclosed |
| EP-4045024-A1 | TRANSDERMAL DELIVERY OF CANNABIDIOL | Pike Therapeutics, Inc., 1219014 B.C. Ltd. (CA) | 2022-08-24 | — | — | EP | disclosed |
| US-20220175718-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF CANCER | PIKE THERAPEUTICS INC (CA) | 2022-06-09 | — | — | US | disclosed |
| WO-2022118303-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS COMPRISING CBD OR THC FOR THE TREATMENT OF CANCER | PIKE THERAPEUTICS, INC. (CA) | 2022-06-09 | — | — | WO | disclosed |
| CN-114555068-A | Transdermal administration of cannabidiol | 长矛治疗股份有限公司1219014 B.C.有限公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2022038475-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | PIKE THERAPEUTICS, INC. (CA) | 2022-02-24 | — | — | WO | disclosed |
| US-20220047541-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | Pike Therapeutics Inc. (CA) | 2022-02-17 | — | — | US | disclosed |
| US-20220047525-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS OF NABILONE ALONE AND IN COMBINATION WITH CANNABINOIDS | PIKE THERAPEUTICS INC (CA) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250248948-A1 | Transdermal and/or Topical, Pharmaceutical Formulations Comprising Cannabidiol and/or Tetrahydrocannabinol for the Treatment of Chronic Pain | CNR2, CNR1, TRPV1 | CNR2 1/4885CDC25A 2828/4885ICMT 1558/4885 |
| US-20260076921-A1 | Transdermal Pharmaceutical Formulations for the Treatment of Multiple Sclerosis | SOST, CNR2, BHMT2 | CNR2 2/4885CDC25A 2776/4885ICMT 700/4885 |
| US-20220175718-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF CANCER | CNR2, CNR1, DSG1 | CNR2 1/4885CDC25A 1069/4885ICMT 1969/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | CNR2 204/4885CDC25A 929/4885ICMT 2228/4885 |
| US-20250186363-A1 | Pharmaceutical Compositions and Methods for Treating Parkinson's Disease | PARK7, SNCA, COMT | CNR2 422/4885CDC25A 2699/4885ICMT 2331/4885 |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | CNR2 1/4885CDC25A 2857/4885ICMT 3409/4885 |
| US-20220047541-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | PARK7, SNCA, COMT | CNR2 422/4885CDC25A 2699/4885ICMT 2331/4885 |
| US-20250312359-A1 | Transdermal Delivery of Tetrahydrocannabinol | CNR2, CNR1, OPRL1 | CNR2 1/4885CDC25A 1958/4885ICMT 957/4885 |
| US-20220047525-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS OF NABILONE ALONE AND IN COMBINATION WITH CANNABINOIDS | CNR2, CNR1, FAAH | CNR2 1/4885CDC25A 2013/4885ICMT 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.